TICKERNERD
Menu
TPSTTPSTHealthcare · Biotechnology

TPST Stock Forecast: Tempest Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.04

The 1 Wall Street analysts covering Tempest Therapeutics, Inc. hold a median 12-month price target of $11 — +957.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$16.6M
Ticker Nerd rank
36 / 100
Median analyst target
$11
Analysts covering
1
Ticker Nerd rank

TPST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tempest Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Accruals
89
Growth
87
Issuance
53
Value
26
Revisions
25
Quality
15
Volatility
13
Momentum
12

Size (90): Smaller than most of the companies we track.

Momentum (12): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TPST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TPST, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $11Median $11High $11

The green dot is the last close — the median target sits +957.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Jan 2026HC Wainwright & Co.UpgradeBuy$11
22 Jan 2026HC Wainwright & Co.UpgradeBuy—
10 Apr 2025HC Wainwright & Co.DowngradeNeutral—
10 Apr 2025ScotiabankDowngradeSector Perform—
28 Mar 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025ScotiabankMaintainsSector Outperform—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024Piper SandlerMaintainsOverweight—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
21 June 2024Piper SandlerReiteratesOverweight—
20 June 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Mar 2024ScotiabankInitiatesSector Outperform—
13 Mar 2024ScotiabankInitiatesSector Outperform—
12 Mar 2024HC Wainwright & Co.MaintainsBuy—
8 Feb 2024JefferiesInitiatesBuy—
11 Oct 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TPST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TPST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Tempest Therapeutics, Inc. (TPST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
18.2×

Cheaper than 6% of US stocks

EV / EBITDA
−1.1×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−931.1%

Higher than 2% of US stocks

Return on assets
−79.4%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TPST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TPSTTempest Therapeutics, Inc.$16.6M
36
PBMPsyence Biomedical Ltd.$16.5M
3
PTNPalatin Technologies, Inc.$16.5M
43
BIVIBioVie, Inc.$16.5M
22
CTXRCitius Pharmaceuticals, Inc.$16.5M
20
LPCNLipocine, Inc.$16.8M
36
ADILAdial Pharmaceuticals, Inc.$16.3M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tempest Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TPST news & analysis

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Tempest Therapeutics reported second quarter 2026 financial results and announced a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T. First patient dosing is anticipated in the fourth quarter of 2026, with initial clinical data expected in the first half of 2027.

Why it matters — The collaboration and upcoming milestones for TPST-4003 signal progress in Tempest's pipeline toward clinical-stage development.

FAQ

Frequently asked questions about TPST stock

What is the TPST stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Tempest Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TPST stock a buy right now?

Of the 1 analysts covering Tempest Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tempest Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TPST?

As at 22 Aug 2026, Tempest Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will TPST stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +957.7% from the last close, and Ticker Nerd's factor model ranks Tempest Therapeutics, Inc. 36 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TPST stock forecast for 2030?

No analyst covering Tempest Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TPST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.

What does Tempest Therapeutics, Inc. do?

Tempest Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies designed to exploit the immune system for cancer treatment.

What is the latest news on TPST?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update". Tempest Therapeutics reported second quarter 2026 financial results and announced a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T. First patient dosing is anticipated in the fourth quarter of 2026, with initial clinical data expected in the first half of 2027.

Company

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies designed to exploit the immune system for cancer treatment. Its primary function is the advancement of oncology programs centered on modulating key immune response pathways that are often dysregulated in cancer. Tempest Therapeutics targets various indications in the immune-oncology landscape, with a pipeline that includes both proprietary small molecules and therapeutic combinations. The company's research and development efforts emphasize precision medicine and the potential to treat a broad spectrum of tumor types, thus impacting cancer treatment strategies significantly. Tempest Therapeutics operates in a highly specialized sector characterized by rapid scientific advancements and regulatory processes, playing a significant role in the biotech industry's pursuit of groundbreaking cancer therapies.

CEO Dr. Matthew Angel Ph.D. · 4 employees · United States · https://www.tempesttx.com